查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1808038

癌症支持治疗药物市场（按药物类别、癌症类型、给药途径、原厂药类型、年龄层、适应症、护理环境、分销管道和最终用户划分）—2025-2030 年全球预测

Cancer Supportive Care Drugs Market by Drug Class, Cancer Type, Route Of Administration, Originator Type, Age Group, Indication, Care Setting, Distribution Channel, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计癌症支持治疗药物市场规模到 2024 年将达到 1.4437 亿美元，到 2025 年将达到 1.5379 亿美元，到 2030 年将达到 2.1387 亿美元，复合年增长率为 6.76%。

主要市场统计数据
基准年2024年 1.4437亿美元
预计2025年 1.5379亿美元
预计2030年 2.1387亿美元
复合年增长率（%） 6.76%

讨论现代癌症治疗过程中对支持性护理不断变化的需求，以保持护理的连续性并改善患者的生活质量

癌症支持治疗作为癌症治疗的重要补充，不断发展演变，注重维持患者功能、最大程度减少治疗中断，并透过持续治疗改善生活品质。抗癌药物治疗的进步、对生存率的日益重视，以及对支持治疗作为基于价值的癌症治疗重要组成部分的广泛认可，共同提升了预防或减轻噁心、感染疾病、骨骼併发症、贫血和疼痛等副作用的药物的临床和商业性重要性。随着治疗方法日益复杂，患者越来越多地在门诊和家中接受治疗，对有效的支持治疗及其提供模式的需求日益增长，迫使相关人员重新审视治疗的可及性、依从性和综合医疗服务提供途径。

检验奖励支持性护理策略和相关人员激励的临床、商业和交付模式的转变

癌症支持治疗领域正在经历变革性变革，这得益于临床创新、不断变化的交付模式以及支付方优先级的不断变化，这些因素共同再形成了支持治疗药物的开发、应用和报销。新型止吐策略和改良的造血药物不断涌现，同时还有骨质改良疗法和种类不断扩展的镇痛选择，所有这些都反映了人们对治疗相关毒性和生存期需求的理解。这些治疗方法进展，加上生物相似药和学名药的扩张，迫使现有製造商优先考虑生命週期管理、患者援助计划和基本契约，以维护其临床和商业性地位。

评估 2025 年关税政策如何改变整个支持性照护社区的供应链动态、采购优先顺序和取得途径。

美国将于2025年实施的政策变革和关税考量，将为整个支持性护理生态系统带来新的营运和策略考量，并在製造、分销和供应商层面产生累积影响。影响进口活性药物原料药、成品药和医疗用品的关税调整，更重视供应链规划与服务成本分析。製造商被迫透过重新审视筹资策略、探索替代供应商关係以及加快二级供应商的资格审核来降低风险。这种重新调整将影响前置作业时间、库存政策以及紧急生产能力的资本配置。

综合多方面细分揭示了支持性护理市场的临床重点、产品差异化和分销策略

依药物类别、癌症类型、给药途径、原厂药类型、年龄层、适应症、护理环境、分销管道和最终用户进行细分，可以建立一个多维图，用于了解临床需求与商业机会和营运限制的交集。在药物类别中，止吐药、骨骼代谢改善剂、血液学药物和疼痛管理药物各自解决不同的临床问题。止吐药类别本身包括 5-HT3 拮抗剂、NK1 拮抗剂和Olanzapine理学亚类，而骨骼代谢改善剂包括双磷酸盐和 RANKL 抑制剂。血液学药物包括促红血球生成剂、骨髓保护剂和血小板生成素受体促效剂包括Darbepoetin和依伯汀等药物。疼痛管理分为非鸦片类药物和鸦片类药物，非鸦片类药物还包括对乙酰胺酚、辅助镇痛药和非类固醇消炎剂。

比较主要地区的监管、报销和交付现实情况，以指导差异化的获取和商业化策略

区域动态正在影响支持性护理药物的开发、核准和交付方式，每个地区都有不同的法规环境、报销模式和医疗服务基础设施。在美洲，先进的癌症护理网络和强大的临床试验生态系统与支付方主导的成本控制并存，迫使製造商在投资于强有力的患者支持和疗效证据的同时，平衡创新与可负担性。门诊和居家医疗已显着转变，推动了对口服製剂、皮下给药方案以及支持远端监控和依从性服务的需求。

描述製造商、专业护理提供者和技术合作伙伴在塑造支持性护理服务方面的策略角色和竞争趋势

关键产业参与者包括原厂製药公司、生物相似药和非专利製造商、专科药房、受託製造厂商和医疗技术提供商，它们各自在支持性护理价值链中提供独特的能力。原厂公司持续利用临床差异化、缓释性和综合病患服务来捍卫其既有的特许专利权。同时，生物相似药和非专利的参与企业透过提供低成本替代品并与批发商和专科经销商建立策略联盟，加大了竞争压力。专科药房和综合护理提供者在协调家庭输液、依从性监测和患者教育方面发挥越来越重要的作用，成为确保支持性护理连续性的关键接触点。

优先考虑围绕证据生成、供应链弹性、扩大患者权益倡导和灵活承包的策略行动，以确保竞争优势

行业领导者应优先考虑一系列切实可行的倡议，以确保患者获得治疗，优化治疗结果，并在不断变化的支持性护理环境中保持商业性可行性。首先，将可靠的真实世界证据纳入产品方案，以证明住院率、治疗中断率和支持性护理负担在临床上显着降低，这将推动付款方参与并支持基于价值的合约。其次，透过供应商多元化、尽可能采用近岸外包以及紧急库存规划来增强供应链的韧性，可以降低政策变革和物流中断带来的脆弱性。第三，扩展患者支援服务，包括财务导航、远端监控和家庭管理协调，可以提高药物依从性和患者满意度，从而增强差异化。

描述一种混合方法，该方法整合了临床文献、专家访谈和交叉检验分析，以深入了解实际的支持性护理。

本研究结合多种方法，整合了支持性治疗相关的临床、营运和商业性洞察。调查方法始于全面的二次研究，涵盖同侪审查的临床文献、监管指导文件、公共公告和权威临床实践指南，以建立循证基础。基准，还进行了一项研究，包括对肿瘤临床医生、专科药剂师、医疗系统处方人员、付款人和行业高管进行结构化访谈，以了解临床未满足需求、获取障碍和商业化策略方面的一线观点。

总结整合策略如何决定不断发展的支持性护理生态系统中的获取和结果

越来越多的分析表明，支持性护理药物是现代癌症治疗的核心，影响着治疗的连续性、患者体验和医疗资源的利用。临床创新，加上医疗服务向门诊和居家模式的转变，对製剂、物流和病患支援的需求日益增长。同时，政策发展和资费考量也带来了新的营运限制，需要在采购、分销和定价方面进行策略性调整。成功的相关人员将是那些整合严谨的真实世界证据、弹性供应链和以病人为中心的服务模式，并向付款人、提供者和病人展示价值的人。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

  • 加速核准长效 G-CSF 生物相似药，以加强化疗嗜中性白血球低下症的治疗
  • 整合数位健康平台来监测和改善患者对支持性护理的依从性
  • 扩大药物基因组学检测的应用，以个人化支持性止吐和镇痛治疗
  • 口服选择性 NK-1 受体拮抗剂缓解化疗引起的噁心的临床开发
  • 使用吸入和经皮製剂减少化疗引起的黏膜炎和黏膜毒性
  • 学名药和生物相似药的市场竞争日益激烈，降低了Pegfilgrastim的治疗成本
  • 一种针对顽固性癌症疼痛和化疗副作用的新型大麻素支持疗法
  • 进行肿瘤高成本支持性护理生物製药报销的真实世界证据研究

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章：2025年美国关税的累积影响

第 8 章：癌症支持治疗药物市场（按药物类别）

  • 止吐药
    • 5-HT3拮抗剂
    • NK1拮抗剂
    • Olanzapine
  • 骨骼代谢改善剂
    • 双磷酸盐
    • RANKL抑制剂
  • 补血剂
    • 促红血球生成因子
      • 达贝泊汀
      • 红血球生成素
    • 骨髓保护剂
    • 血小板生成素受体促效剂
  • 疼痛管理药物
    • 非阿片类药物
      • 乙酰胺酚
      • 辅助止痛药
      • 非类固醇消炎剂（NSAID）
    • 阿片类药物

第九章 癌症支持治疗药物市场（按癌症类型）

  • 造血系统恶性肿瘤
    • 白血病
    • 淋巴瘤
    • 多发性骨髓瘤
    • 骨髓发育不良症候群
  • 固态肿瘤
    • 乳癌
    • 大肠直肠癌
    • 消化系统癌症
    • 头颈癌
    • 肺癌
    • 卵巢癌
    • 摄护腺癌

第 10 章 癌症支持治疗药物市场（依给药途径）

  • 静脉
  • 口服
  • 直肠
  • 皮下
  • 局部的
  • 经皮

第 11 章 癌症支持治疗药物市场（按原始药物类型）

  • 生物相似药
  • 品牌
  • 非专利的

第十二章 癌症支持治疗药物市场（依年龄层）

  • 成人
  • 老年人
  • 孩子们

第十三章 癌症支持治疗药物市场（按适应症）

  • 骨转移相关事件
  • 恶病质和食慾不振
  • 癌症痛
  • 化疗引起的噁心和呕吐
    • 急性CINV
    • 特发性/难治性 CINV
    • 迟发性CINV
  • 腹泻
  • 黏膜炎/口腔炎
  • 骨髓抑制
    • 化疗引起的贫血
    • 化疗引起的嗜中性白血球低下症

14. 癌症支持治疗药物市场（依护理环境）

  • 住院病人
  • 门诊

第十五章 癌症支持治疗药物市场（依通路）

  • 医院药房
  • 通讯/网路药局
  • 零售药局
  • 专业药房

第十六章 癌症支持治疗药物市场（依最终使用者）

  • 门诊手术中心
  • 居家照护环境
  • 医院
  • 癌症诊所/输液中心

第 17 章：美洲癌症支持治疗药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

18. 欧洲、中东和非洲癌症支持治疗药物市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

19. 亚太地区癌症支持治疗药物市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第二十章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Amgen Inc.
    • Novartis AG
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson Services, Inc.
    • Sanofi SA
    • GlaxoSmithKline plc
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Fresenius Kabi AG
    • Heron Therapeutics, Inc.
    • Helsinn Healthcare SA
    • AstraZeneca plc
    • Ipsen SA
    • Dr. Reddy's Laboratories Ltd.
    • Acacia Pharma Group Plc
    • Fresenius SE & Co. KGaA
    • Lupin Limited
    • Daiichi Sankyo Company, Limited
    • APR Applied Pharma Research SA by Relief Therapeutics Holding AG
    • Abbott Laboratories
    • Accord Healthcare Limited
    • Coherus BioSciences, Inc.

第21章 研究人工智慧

第22章 研究统计

第23章 研究联络人

第24章 研究报导

第25章 附录

Product Code: MRR-450A0628C601

The Cancer Supportive Care Drugs Market was valued at USD 144.37 million in 2024 and is projected to grow to USD 153.79 million in 2025, with a CAGR of 6.76%, reaching USD 213.87 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 144.37 million
Estimated Year [2025] USD 153.79 million
Forecast Year [2030] USD 213.87 million
CAGR (%) 6.76%

Framing the evolving imperative for supportive therapies that preserve treatment continuity and enhance patient quality of life across modern oncology care

Cancer supportive care continues to evolve as a critical complement to oncologic therapy, focusing on preserving patient function, minimizing treatment interruptions, and improving quality of life across the treatment continuum. Advances in anticancer therapeutics, rising emphasis on survivorship, and broader recognition of supportive care as an integral component of value-based oncology care have collectively elevated the clinical and commercial importance of drugs that prevent or mitigate adverse effects such as nausea, infection, bone complications, anemia, and pain. As treatment regimens become more complex and patients increasingly receive therapy in outpatient or home settings, the need for effective supportive agents and delivery models has intensified, prompting stakeholders to re-examine pathways for access, adherence, and integrated care delivery.

Regulatory attention and payer scrutiny have shifted the conversation from episodic symptom control to longitudinal management strategies that reduce hospitalizations and enable continued cancer-directed therapy. Meanwhile, technological enablers such as telemedicine, remote monitoring, and digital adherence tools are being woven into supportive care pathways to detect complications early and to triage interventions. These developments are influencing clinical practice guidelines, hospital formularies, and procurement strategies, while simultaneously shaping expectations among patients and caregivers for a higher standard of symptom management. Consequently, supportive care drugs are no longer ancillary commodities but constitute strategic assets in optimizing treatment outcomes and sustaining healthcare system efficiencies.

Examining the clinical, commercial, and delivery model transformations that are redefining supportive care strategies and stakeholder incentives

The landscape of cancer supportive care has undergone transformative shifts driven by clinical innovation, delivery model changes, and evolving payer priorities that collectively reshape how supportive medicines are developed, adopted, and reimbursed. Novel antiemetic strategies and refinements in hematopoietic agents are emerging alongside an expanding portfolio of bone-modifying therapies and diversified analgesic options, all of which reflect a more nuanced understanding of treatment-related toxicities and survivorship needs. These therapeutic advances are complemented by an expansion of biosimilars and generics that force incumbent manufacturers to prioritize lifecycle management, patient support programs, and value-based contracting to defend clinical and commercial positioning.

Concurrent shifts in care delivery have profound implications. An acceleration of outpatient infusion, homecare services, and remote monitoring has prompted manufacturers and providers to redesign packaging, dosing regimens, and adherence support to accommodate decentralized treatment environments. Payer emphasis on outcomes and cost containment is incentivizing real-world evidence generation and performance-based agreements, which in turn influence clinical guideline adoption and formulary decisions. Supply chain resilience and manufacturing flexibility have become strategic priorities in light of geopolitical pressures and episodic disruptions, increasing interest in diversified sourcing, nearshoring, and capacity partnering with contract manufacturers. Taken together, these shifts signal a more integrated, multidisciplinary approach to supportive care that aligns clinical efficacy with operational feasibility and economic sustainability.

Assessing how tariff policy shifts in 2025 altered supply chain dynamics, procurement priorities, and access pathways across supportive care stakeholders

Policy changes and tariff considerations introduced in the United States in 2025 have injected a new set of operational and strategic calculations across the supportive care ecosystem, with cumulative impacts felt at the manufacturing, distribution, and provider levels. Tariff adjustments affecting imported active pharmaceutical ingredients, finished formulations, and medical supplies have increased the emphasis on supply chain mapping and cost-to-serve analysis. Manufacturers have been prompted to reassess sourcing strategies, pursue alternative supplier relationships, and accelerate qualification of secondary suppliers to mitigate exposure. This recalibration has implications for lead times, inventory policies, and capital allocation for contingency manufacturing capacity.

These policy-induced cost pressures have reverberated through distribution channels and procurement cycles, elevating negotiation intensity between manufacturers, distributors, and payers. Health systems and specialty pharmacies have intensified their focus on formulary optimization and total cost-of-care calculations to preserve access while managing budgets. At the clinical interface, providers have become more attentive to therapeutic equivalence and to opportunities for substituting lower-cost generics or biosimilars where clinically appropriate. Patient support mechanisms have also been affected as companies re-evaluate copay assistance programs and logistical support for home administration to ensure affordability and continuity of therapy.

In response to tariff-driven uncertainty, some stakeholders have advocated for policy engagement and collaborative solutions, such as tariff exemptions for critical medical inputs, incentives for domestic manufacturing, and streamlined regulatory pathways for rapid supplier qualification. These strategies aim to balance the goals of national industrial policy with the imperative to maintain patient access and clinical quality. Looking ahead, organizations that proactively adapt procurement, contractual frameworks, and patient support models will be better positioned to navigate sustained policy variability while safeguarding treatment continuity for vulnerable patient populations.

Integrating multi-dimensional segmentation to illuminate clinical priorities, product differentiation, and distribution strategies across supportive care markets

Segmentation across drug class, cancer type, route of administration, originator type, age group, indication, care setting, distribution channel, and end user creates a multidimensional map for understanding where clinical needs intersect with commercial opportunity and operational constraints. Within drug class, antiemetics, bone-modifying agents, hematopoietic agents, and pain management agents each address distinct clinical problems; the antiemetic category itself includes pharmacologic subclasses such as 5-HT3 antagonists, NK1 antagonists, and olanzapine, while bone-modifying therapies encompass bisphosphonates and RANKL inhibitors. Hematopoietic support spans erythropoiesis stimulating agents, myeloprotection agents, and thrombopoietin receptor agonists, and erythropoiesis stimulating agents are characterized by formulations such as darbepoetin and epoetin. Pain management divides into non-opioid and opioid approaches, with non-opioids further characterized by acetaminophen, adjuvant analgesics, and nonsteroidal anti-inflammatory drugs.

Cancer type segmentation distinguishes hematologic malignancies and solid tumors, with hematologic categories covering leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes, while solid tumors include breast, colorectal, gastrointestinal, head and neck, lung, ovarian, and prostate cancers, each of which presents unique supportive care priorities and guideline-driven interventions. Route of administration intersects with care setting considerations, spanning intravenous, oral, rectal, subcutaneous, topical, and transdermal modalities, and prompting different patient education, adherence, and logistics needs. Originator type-biosimilar, branded, and generic-shapes pricing dynamics and contracting strategies, while age-group segmentation across adult, geriatric, and pediatric populations demands tailored dosing, safety monitoring, and caregiver support.

Indication-based segmentation addresses complications such as bone metastases related events, cachexia and anorexia, cancer pain, chemotherapy-induced nausea and vomiting with its acute, breakthrough/refractory, and delayed subcategories, diarrhea, mucositis and stomatitis, and myelosuppression including chemotherapy-induced anemia and neutropenia; each indication imposes specific efficacy, safety, and delivery expectations. Distribution channel and end-user segmentation illuminate commercial pathways, with hospital pharmacies, mail-order and online pharmacies, retail pharmacies, and specialty pharmacies interacting with ambulatory surgery centers, homecare settings, hospitals, and oncology clinics and infusion centers. Integrating these segmentation lenses enables stakeholders to prioritize product development, align patient support programs, and design distribution strategies that reflect clinical workflows and payer requirements.

Comparing the regulatory, reimbursement, and delivery realities across major regions to guide differentiated access and commercialization strategies

Regional dynamics shape how supportive care drugs are developed, approved, and delivered, with each geography presenting distinct regulatory environments, reimbursement paradigms, and care delivery infrastructures. In the Americas, advanced oncology care networks and strong clinical trial ecosystems coexist with payer-driven cost containment, driving manufacturers to balance innovation with affordability and to invest in robust patient support and outcomes evidence. Shifts toward outpatient and home-based care are pronounced, amplifying demand for oral formulations, subcutaneous options, and services that enable remote monitoring and adherence support.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and diverse market access pathways require differentiated strategies that account for national reimbursement rules, tendering mechanisms, and varying levels of healthcare infrastructure. Manufacturers often pursue regionally tailored evidence generation and pricing strategies to secure formulary inclusion, and partnerships with regional distributors and specialty pharmacies are common to bridge logistical gaps and enhance reach. In the Asia-Pacific region, rapid healthcare modernization, expanding oncology service capacity, and growing attention to biosimilar adoption create both opportunities and complexities. Regulatory harmonization efforts coexist with country-specific procurement models, and manufacturers are incentivized to develop flexible supply arrangements and locally relevant patient support services to accelerate uptake and sustain access amid evolving payer expectations.

Profiling the strategic roles and competitive moves of manufacturers, specialty providers, and technology partners shaping supportive care delivery

Key industry participants span originator pharmaceutical companies, biosimilar manufacturers, generic producers, specialty pharmacies, contract manufacturing organizations, and healthcare technology providers, each contributing distinct capabilities to the supportive care value chain. Originator firms continue to leverage clinical differentiation, extended-release formulations, and integrated patient services to defend established franchises, while biosimilar and generic entrants intensify competitive pressure by offering lower-cost alternatives and by pursuing strategic partnerships with wholesalers and specialty distributors. Specialty pharmacies and integrated care providers play an increasingly important role in coordinating home infusion, adherence monitoring, and patient education, serving as critical touchpoints for ensuring continuity of supportive therapy.

Contract manufacturing and outsourcing partners have expanded capacity to meet demand for flexible production and regulatory compliance, enabling companies to respond more rapidly to supply disruptions and to local content requirements. Technology providers supplying remote monitoring, telehealth platforms, and digital adherence tools are forging collaborations with manufacturers and providers to support decentralized care models. Across this ecosystem, leading organizations are distinguishing themselves through investments in real-world evidence, comprehensive patient support programs that address affordability and logistics, and value-based contracting approaches that align reimbursement with clinical outcomes. These strategic moves reflect a broader emphasis on integrated care pathways, where drug efficacy must be matched by delivery capabilities and demonstrable impact on patient-relevant endpoints.

Prioritizing strategic actions on evidence generation, supply chain resilience, patient support expansion, and flexible contracting to secure competitive advantage

Industry leaders should prioritize a set of actionable initiatives to secure access, optimize patient outcomes, and sustain commercial viability in a changing supportive care environment. First, embedding robust real-world evidence generation into product programs will facilitate payer engagement and support value-based agreements by demonstrating clinically meaningful reductions in hospitalizations, treatment interruptions, and supportive care burden. Second, strengthening supply chain resilience through supplier diversification, nearshoring where feasible, and contingency inventory planning will reduce vulnerability to policy shifts and logistic disruptions. Third, expanding patient support services that encompass financial navigation, remote monitoring, and coordinated home administration will improve adherence and patient satisfaction while reinforcing differentiation.

In parallel, organizations should adopt flexible pricing and contracting frameworks that account for total cost of care and enable outcome-based arrangements with payers and providers. Product teams must align formulation development and packaging innovations with the realities of outpatient and home care to enhance usability and safety. Strategic alliances with specialty pharmacies, homecare providers, and technology vendors can accelerate adoption of decentralized care models and provide seamless patient experiences. Executing these recommendations requires cross-functional coordination across commercial, medical, regulatory, and supply chain teams, and a willingness to pilot new commercial models in partnership with payers and provider systems to generate the evidence and operational learnings necessary for scale.

Explaining the mixed-methods approach that combines clinical literature, expert interviews, and cross-validated analysis to produce actionable supportive care insights

This research integrates a multi-method approach to synthesize clinical, operational, and commercial insights relevant to supportive care therapeutics. The methodology begins with comprehensive secondary research drawn from peer-reviewed clinical literature, regulatory guidance documents, public policy announcements, and authoritative clinical practice guidelines to establish an evidence-based foundation. This baseline was complemented by primary research consisting of structured interviews with oncology clinicians, specialty pharmacists, health system formulary decision-makers, payers, and industry executives to capture frontline perspectives on clinical unmet needs, access barriers, and commercialization tactics.

Analytical methods included qualitative thematic analysis to surface recurring themes and strategic priorities, and cross-validation using triangulation across data sources to ensure consistency and reduce bias. Segmentation frameworks were constructed by mapping therapeutic classes, clinical indications, administration routes, and care settings to real-world care pathways, allowing for scenario analysis of distribution and access models. Validation steps involved iterative review with independent clinical advisors and supply chain specialists to refine assumptions about operational feasibility and to corroborate strategic interpretations. Where applicable, regulatory and policy analyses were incorporated to contextualize potential impacts on procurement, manufacturing, and patient access.

Summarizing how integrated clinical, operational, and commercial strategies will determine access and outcomes in the evolving supportive care ecosystem

The cumulative analysis underscores that supportive care drugs are central to contemporary oncology practice, influencing treatment continuity, patient experience, and healthcare resource utilization. Clinical innovation, coupled with shifts in care delivery toward outpatient and home-based models, has elevated requirements for formulations, logistics, and patient support. Concurrently, policy developments and tariff considerations have introduced new operational constraints that necessitate strategic adaptation across sourcing, distribution, and pricing. Stakeholders that succeed will be those that integrate rigorous real-world evidence, resilient supply chains, and patient-centric service models to demonstrate value to payers, providers, and patients.

Looking ahead, the convergence of clinical, commercial, and operational trends points to a future in which supportive care strategies are tightly aligned with broader oncology objectives: enabling sustained delivery of cancer-directed therapies, mitigating adverse events, and optimizing total cost of care. Organizations that proactively reconfigure their portfolios, partnerships, and evidence-generation strategies to reflect decentralized care realities and evolving reimbursement expectations will be best positioned to deliver meaningful improvements in patient outcomes while sustaining long-term competitiveness.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Accelerated approval of long-acting G-CSF biosimilars enhancing neutropenia management in chemotherapy
  • 5.2. Integration of digital health platforms to monitor and improve patient adherence to supportive care regimens
  • 5.3. Expanding use of pharmacogenomic testing to personalize antiemetic and analgesic supportive care therapies
  • 5.4. Clinical development of oral selective NK-1 receptor antagonists for multidrug chemotherapy-induced nausea relief
  • 5.5. Adoption of inhaled and transdermal formulations to mitigate chemotherapy-induced mucositis and mucosal toxicity
  • 5.6. Growing market competition from generic and biosimilar pegfilgrastim alternatives reducing treatment costs
  • 5.7. Emerging cannabinoid-based supportive therapies targeting refractory cancer pain and chemotherapy side effects
  • 5.8. Implementation of real-world evidence studies for reimbursement of high-cost supportive care biologics in oncology

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Cancer Supportive Care Drugs Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Antiemetics
    • 8.2.1. 5-HT3 Antagonists
    • 8.2.2. NK1 Antagonists
    • 8.2.3. Olanzapine
  • 8.3. Bone-Modifying Agents
    • 8.3.1. Bisphosphonates
    • 8.3.2. RANKL Inhibitors
  • 8.4. Hematopoietic Agents
    • 8.4.1. Erythropoiesis Stimulating Agents
      • 8.4.1.1. Darbepoetin
      • 8.4.1.2. Epoetin
    • 8.4.2. Myeloprotection Agents
    • 8.4.3. Thrombopoietin Receptor Agonists
  • 8.5. Pain Management Agents
    • 8.5.1. Non-Opioids
      • 8.5.1.1. Acetaminophen
      • 8.5.1.2. Adjuvant Analgesics
      • 8.5.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 8.5.2. Opioids

9. Cancer Supportive Care Drugs Market, by Cancer Type

  • 9.1. Introduction
  • 9.2. Hematologic Malignancies
    • 9.2.1. Leukemias
    • 9.2.2. Lymphomas
    • 9.2.3. Multiple Myeloma
    • 9.2.4. Myelodysplastic Syndromes
  • 9.3. Solid Tumors
    • 9.3.1. Breast Cancer
    • 9.3.2. Colorectal Cancer
    • 9.3.3. Gastrointestinal Cancers
    • 9.3.4. Head And Neck Cancer
    • 9.3.5. Lung Cancer
    • 9.3.6. Ovarian Cancer
    • 9.3.7. Prostate Cancer

10. Cancer Supportive Care Drugs Market, by Route Of Administration

  • 10.1. Introduction
  • 10.2. Intravenous
  • 10.3. Oral
  • 10.4. Rectal
  • 10.5. Subcutaneous
  • 10.6. Topical
  • 10.7. Transdermal

11. Cancer Supportive Care Drugs Market, by Originator Type

  • 11.1. Introduction
  • 11.2. Biosimilar
  • 11.3. Branded
  • 11.4. Generic

12. Cancer Supportive Care Drugs Market, by Age Group

  • 12.1. Introduction
  • 12.2. Adult
  • 12.3. Geriatric
  • 12.4. Pediatric

13. Cancer Supportive Care Drugs Market, by Indication

  • 13.1. Introduction
  • 13.2. Bone Metastases Related Events
  • 13.3. Cachexia & Anorexia
  • 13.4. Cancer Pain
  • 13.5. Chemotherapy-Induced Nausea & Vomiting
    • 13.5.1. Acute CINV
    • 13.5.2. Breakthrough/Refractory CINV
    • 13.5.3. Delayed CINV
  • 13.6. Diarrhea
  • 13.7. Mucositis And Stomatitis
  • 13.8. Myelosuppression
    • 13.8.1. Chemotherapy-Induced Anemia
    • 13.8.2. Chemotherapy-Induced Neutropenia

14. Cancer Supportive Care Drugs Market, by Care Setting

  • 14.1. Introduction
  • 14.2. Inpatient
  • 14.3. Outpatient

15. Cancer Supportive Care Drugs Market, by Distribution Channel

  • 15.1. Introduction
  • 15.2. Hospital Pharmacies
  • 15.3. Mail-Order And Online Pharmacies
  • 15.4. Retail Pharmacies
  • 15.5. Specialty Pharmacies

16. Cancer Supportive Care Drugs Market, by End User

  • 16.1. Introduction
  • 16.2. Ambulatory Surgery Centers
  • 16.3. Homecare Settings
  • 16.4. Hospitals
  • 16.5. Oncology Clinics And Infusion Centers

17. Americas Cancer Supportive Care Drugs Market

  • 17.1. Introduction
  • 17.2. United States
  • 17.3. Canada
  • 17.4. Mexico
  • 17.5. Brazil
  • 17.6. Argentina

18. Europe, Middle East & Africa Cancer Supportive Care Drugs Market

  • 18.1. Introduction
  • 18.2. United Kingdom
  • 18.3. Germany
  • 18.4. France
  • 18.5. Russia
  • 18.6. Italy
  • 18.7. Spain
  • 18.8. United Arab Emirates
  • 18.9. Saudi Arabia
  • 18.10. South Africa
  • 18.11. Denmark
  • 18.12. Netherlands
  • 18.13. Qatar
  • 18.14. Finland
  • 18.15. Sweden
  • 18.16. Nigeria
  • 18.17. Egypt
  • 18.18. Turkey
  • 18.19. Israel
  • 18.20. Norway
  • 18.21. Poland
  • 18.22. Switzerland

19. Asia-Pacific Cancer Supportive Care Drugs Market

  • 19.1. Introduction
  • 19.2. China
  • 19.3. India
  • 19.4. Japan
  • 19.5. Australia
  • 19.6. South Korea
  • 19.7. Indonesia
  • 19.8. Thailand
  • 19.9. Philippines
  • 19.10. Malaysia
  • 19.11. Singapore
  • 19.12. Vietnam
  • 19.13. Taiwan

20. Competitive Landscape

  • 20.1. Market Share Analysis, 2024
  • 20.2. FPNV Positioning Matrix, 2024
  • 20.3. Competitive Analysis
    • 20.3.1. Amgen Inc.
    • 20.3.2. Novartis AG
    • 20.3.3. Pfizer Inc.
    • 20.3.4. F. Hoffmann-La Roche Ltd.
    • 20.3.5. Johnson & Johnson Services, Inc.
    • 20.3.6. Sanofi S.A.
    • 20.3.7. GlaxoSmithKline plc
    • 20.3.8. Teva Pharmaceutical Industries Ltd.
    • 20.3.9. Viatris Inc.
    • 20.3.10. Fresenius Kabi AG
    • 20.3.11. Heron Therapeutics, Inc.
    • 20.3.12. Helsinn Healthcare SA
    • 20.3.13. AstraZeneca plc
    • 20.3.14. Ipsen S.A.
    • 20.3.15. Dr. Reddy's Laboratories Ltd.
    • 20.3.16. Acacia Pharma Group Plc
    • 20.3.17. Fresenius SE & Co. KGaA
    • 20.3.18. Lupin Limited
    • 20.3.19. Daiichi Sankyo Company, Limited
    • 20.3.20. APR Applied Pharma Research S.A. by Relief Therapeutics Holding AG
    • 20.3.21. Abbott Laboratories
    • 20.3.22. Accord Healthcare Limited
    • 20.3.23. Coherus BioSciences, Inc.

21. ResearchAI

22. ResearchStatistics

23. ResearchContacts

24. ResearchArticles

25. Appendix

LIST OF FIGURES

  • FIGURE 1. CANCER SUPPORTIVE CARE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 20. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 22. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 26. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 29. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 30. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 31. CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 33. CANCER SUPPORTIVE CARE DRUGS MARKET: RESEARCHAI
  • FIGURE 34. CANCER SUPPORTIVE CARE DRUGS MARKET: RESEARCHSTATISTICS
  • FIGURE 35. CANCER SUPPORTIVE CARE DRUGS MARKET: RESEARCHCONTACTS
  • FIGURE 36. CANCER SUPPORTIVE CARE DRUGS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. CANCER SUPPORTIVE CARE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OLANZAPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OLANZAPINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DARBEPOETIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DARBEPOETIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY EPOETIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY EPOETIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOPROTECTION AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOPROTECTION AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THROMBOPOIETIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THROMBOPOIETIN RECEPTOR AGONISTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LEUKEMIAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LEUKEMIAS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LYMPHOMAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LYMPHOMAS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RECTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RECTAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE METASTASES RELATED EVENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE METASTASES RELATED EVENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CACHEXIA & ANOREXIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CACHEXIA & ANOREXIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER PAIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE CINV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE CINV, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAKTHROUGH/REFRACTORY CINV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAKTHROUGH/REFRACTORY CINV, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DELAYED CINV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DELAYED CINV, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DIARRHEA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MUCOSITIS AND STOMATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MUCOSITIS AND STOMATITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED ANEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED ANEMIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 149. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 151. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2025-2030 (USD MILLION)
  • TABLE 153. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2025-2030 (USD MILLION)
  • TABLE 155. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 157. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 159. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 161. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 163. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MAIL-ORDER AND ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MAIL-ORDER AND ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 165. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 167. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 169. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 171. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 173. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 175. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 177. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONCOLOGY CLINICS AND INFUSION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONCOLOGY CLINICS AND INFUSION CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 179. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 181. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
  • TABLE 183. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 185. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2025-2030 (USD MILLION)
  • TABLE 187. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 189. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2025-2030 (USD MILLION)
  • TABLE 191. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2025-2030 (USD MILLION)
  • TABLE 193. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 195. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
  • TABLE 197. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
  • TABLE 199. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 201. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 205. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 207. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2025-2030 (USD MILLION)
  • TABLE 209. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2025-2030 (USD MILLION)
  • TABLE 211. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2025-2030 (USD MILLION)
  • TABLE 213. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 215. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 217. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
  • TABLE 237. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
  • TABLE 239. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 241. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 243. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 259. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 261. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
  • TABLE 262. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
  • TABLE 263. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 264. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 265. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 266. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2025-2030 (USD MILLION)
  • TABLE 267. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 268. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 269. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2024 (USD MILLION)
  • TABLE 270. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2025-2030 (USD MILLION)
  • TABLE 271. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 272. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2025-2030 (USD MILLION)
  • TABLE 273. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 276. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
  • TABLE 277. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 278. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
  • TABLE 279. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 281. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 283. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 285. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 286. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 287. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2024 (USD MILLION)
  • TABLE 288. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2025-2030 (USD MILLION)
  • TABLE 289. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 290. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2025-2030 (USD MILLION)
  • TABLE 291. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2024 (USD MILLION)
  • TABLE 292. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2025-2030 (USD MILLION)
  • TABLE 293. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 295. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)

TABLE